Multiple Sclerosis

The MS pipeline is converging on the central goal of halting smoldering, compartmentalized CNS inflammation that drives progression independent of relapse activity (PIRA). GCNN 2027 will review head-to-head data on anti-CD20 therapies (ocrelizumab, ofatumumab, ublituximab) and the maturing BTK inhibitor class — tolebrutinib (GEMINI, HERCULES), evobrutinib, fenebrutinib and remibrutinib — which uniquely penetrate the CNS to target microglia and B cells. The track also covers EBV as a causal driver, remyelination strategies, and the role of serum neurofilament light and GFAP as routine monitoring biomarkers.